Abstract Body

Background: Two CXCR4 isoforms have been described in humans, CXCR4-A and CXCR4-B, corresponding to an unspliced and a spliced mRNA, respectively. In this study we analyzed the expression of both isoforms, and their functions as HIV coreceptors and chemokine receptors. Methodology: To this aim, using HIV gene transfer vectors, we established two cell lines expressing each isoform. HIV infectibility by replicative and nonreplicative X4 strains was measured in both cell lines, and the amount of early reverse transcripts was quantified as a marker of viral entry. The capacity of both cell lines to support R5 to X4 switch was studied in vitro. Chemotaxis assays were performed. Expression of the two forms of CXCR4 mRNA was evaluated by specific RT-PCR. R5/X4 genotype was defined in HIV-infected persons by determining the False-Positive Rate (FPR) score calculated by the Geno2Pheno algorithm using the sequence of the V3 region of the envelope. Results: We showed that CXCR4-B, but not CXCR4-A, mediates an efficient HIV-1 X4 entry and productive infection. Yet, the chemotactic activity of CXCL12 on both isoforms was similar. In vitro infection with an R5 strain increased CXCR4-B : CXCR4-A mRNA ratio in peripheral blood mononuclear cells (PBMC), and this ratio correlated with HIV RNA plasma level in R5-infected individuals. In addition, the presence of the CXCR4-B isoform favored R5 to X4 switch more efficiently than CXCR4-A in vitro. Moreover, the capability of circulating HIV-1 strains to use CXCR4, determined after the FPR, was linked to the predominance of CXCR4-B over CXCR4-A expression in PBMC. Finally, we achieved a specific siRNA-mediated knockdown of CXCR4-B. Conclusions: CXCR4 isoforms present with similar chemokine receptor but different HIV coreceptor capabilities. Our data support the hypothesis that HIV-R5 infection favors CXCR4-B expression over that of CXCR4-A, a phenomenon that could facilitate R5 to X4 switch. We also established a proof of concept for a possible gene therapeutic approach aimed at specifically blocking the HIV coreceptor activity of CXCR4-B.